Difference between revisions of "Team:BGU Israel"
| Line 1: | Line 1: | ||
| − | |||
<!DOCTYPE html> | <!DOCTYPE html> | ||
<html lang="en"> | <html lang="en"> | ||
| Line 212: | Line 211: | ||
background-repeat: no-repeat; | background-repeat: no-repeat; | ||
background-size: cover; | background-size: cover; | ||
| + | |||
| + | } | ||
| + | |||
| + | |||
| + | @media only screen and (max-device-width: 1366px) { | ||
| + | .masthead { | ||
| + | background-attachment: scroll; | ||
| + | } | ||
} | } | ||
| Line 237: | Line 244: | ||
} | } | ||
footer { | footer { | ||
| − | + | padding-top: 10rem; | |
| − | + | padding-bottom: calc(10rem - 56px); | |
| − | + | background-image:url('dark-lab.jpg'); | |
| − | .navbar-default .navbar-nav>.open>a, .navbar-default .navbar-nav>.open>a:focus, .navbar-default .navbar-nav>.open>a:hover { | + | width:100%; |
| + | overflow: hidden; | ||
| + | min-height: 400px; | ||
| + | /* Create the parallax scrolling effect */ | ||
| + | background-attachment: fixed; | ||
| + | background-position: center; | ||
| + | background-repeat: no-repeat; | ||
| + | background-size: cover; | ||
| + | } | ||
| + | |||
| + | .navbar-default .navbar-nav>.open>a, .navbar-default .navbar-nav>.open>a:focus, .navbar-default .navbar-nav>.open>a:hover { | ||
background: #fff !important; | background: #fff !important; | ||
color:#0186ac !important; | color:#0186ac !important; | ||
| Line 261: | Line 278: | ||
text-transform: capitalize; | text-transform: capitalize; | ||
font-size:18px; | font-size:18px; | ||
| + | } | ||
| + | #mainMenu .dropdown-menu li:hover { | ||
| + | color:#0186ac !important; | ||
| + | background: transparent; | ||
} | } | ||
} | } | ||
| Line 271: | Line 292: | ||
<body id="myPage" data-spy="scroll" data-target=".navbar" data-offset="60"> | <body id="myPage" data-spy="scroll" data-target=".navbar" data-offset="60"> | ||
<div id="top"></div> | <div id="top"></div> | ||
| − | < | + | <a id="myBtn" href="#top" title="To Top"> |
<span class="glyphicon glyphicon-chevron-up"></span> | <span class="glyphicon glyphicon-chevron-up"></span> | ||
| − | </ | + | </a> |
<nav id="mainMenu" class="navbar navbar-default navbar-fixed-top"> | <nav id="mainMenu" class="navbar navbar-default navbar-fixed-top"> | ||
| Line 376: | Line 397: | ||
.footer-list { | .footer-list { | ||
list-style: none; | list-style: none; | ||
| − | color:# | + | color:#fff; |
} | } | ||
.footer-list-item { | .footer-list-item { | ||
padding:20px 0 20px 0 !important; | padding:20px 0 20px 0 !important; | ||
| − | border-bottom: 1px solid # | + | border-bottom: 1px solid #fff; |
} | } | ||
.footer-list .footer-list-item:last-child { | .footer-list .footer-list-item:last-child { | ||
| Line 387: | Line 408: | ||
</style> | </style> | ||
| − | <footer class="container- | + | <footer> |
| + | <div class="container my-auto"> | ||
<div class="row"> | <div class="row"> | ||
<div class="col-md-4"> | <div class="col-md-4"> | ||
| Line 414: | Line 436: | ||
</div> | </div> | ||
| + | </div> | ||
</footer> | </footer> | ||
Revision as of 08:46, 31 July 2018
<!DOCTYPE html>
Abstract
Recent research studies of Amyotrophic Lateral Sclerosis (ALS) suggest that brain cells that have become toxic, directly contribute to the progression of the disease. These cells change their gene expression pattern and possess distinguishing genetic markers. In addition, they drive the death of other cells in the brain among them the motor neurons.
Our objective, as the BGU-IGEM team OriginALS, is to prolong survival of ALS patients via a novel genetic engineering approach. In order to reach this objective, we combine two separate strategies as our therapeutic approach:
- We identify and selectively eliminate only the toxic cells. In order to identify and target the toxic-cells only, we use distinguishing markers that are unique only to them.
- We prevent the generation of new toxic cells by genetically targeting specific molecules that generate the toxic cells.
In conclusion, our approach combines an apoptotic destruction of toxic cells with the prevention of the formation of new toxic cells, thus aiming to significantly reduce the occurrence of toxic cells in the central neuronal system (CNS), which is aimed at a significant deceleration of the progression rate of ALS.